BE1002375A3 - Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie. - Google Patents

Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie. Download PDF

Info

Publication number
BE1002375A3
BE1002375A3 BE8800975A BE8800975A BE1002375A3 BE 1002375 A3 BE1002375 A3 BE 1002375A3 BE 8800975 A BE8800975 A BE 8800975A BE 8800975 A BE8800975 A BE 8800975A BE 1002375 A3 BE1002375 A3 BE 1002375A3
Authority
BE
Belgium
Prior art keywords
materials
inhs
biological materials
methods
therapy
Prior art date
Application number
BE8800975A
Other languages
English (en)
Inventor
Jean-Michel Dayer
Philippe Lucien Seckinger
Gonzalo Jose Mazzei
Alan Reed Shaw
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22218720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1002375(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of BE1002375A3 publication Critical patent/BE1002375A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne les inhibiteurs de l'interleukine 1 (IL-1 INHs) inhibant de manière sélective l'activité de l'interleukine 1. L'invention concerne également des procédés permettant de purifier de tels IL-1 INHs à partir d'urine et de produire de tels IL-1 INHs au moyen d'hôtes transformés avec des molécules d'ADN recombinant comportant des séquences ADN codant pour les inhibiteurs, ainsi que des méthodes de traitement et des compositions caractérisées par de tels IL-1 INHs. Ces méthodes et agents sont utiles dans les applications et les thérapies immunosuppressives et anti-inflammatoires.
BE8800975A 1987-08-26 1988-08-26 Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie. BE1002375A3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8963287A 1987-08-26 1987-08-26

Publications (1)

Publication Number Publication Date
BE1002375A3 true BE1002375A3 (fr) 1991-01-22

Family

ID=22218720

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8800975A BE1002375A3 (fr) 1987-08-26 1988-08-26 Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.

Country Status (20)

Country Link
EP (1) EP0341273B1 (fr)
JP (2) JP3014099B2 (fr)
KR (2) KR0138654B1 (fr)
AT (1) ATE147408T1 (fr)
AU (1) AU633471B2 (fr)
BE (1) BE1002375A3 (fr)
CA (1) CA1341026C (fr)
DE (1) DE3855747T2 (fr)
DK (1) DK175837B1 (fr)
ES (3) ES2015348A6 (fr)
FR (1) FR2621821A1 (fr)
GB (1) GB2220662A (fr)
HK (1) HK1007748A1 (fr)
IL (1) IL87543A0 (fr)
IT (1) IT1226855B (fr)
NL (1) NL8820676A (fr)
NZ (1) NZ225940A (fr)
SE (1) SE8901342D0 (fr)
WO (1) WO1989001946A1 (fr)
ZA (1) ZA886251B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
HU215434B (hu) * 1988-05-27 1999-04-28 Synergen Inc. Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
BR9007883A (pt) * 1989-11-29 1992-09-29 Synergen Inc Producao de inibidor de interleucina-1 humana recombinante
US5714140A (en) * 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1991017184A1 (fr) * 1990-04-27 1991-11-14 The Upjohn Company Inhibiteurs ameliores d'interleukine-1
WO1991017249A1 (fr) * 1990-05-01 1991-11-14 Cetus Corporation Antagoniste d'interleucine-1 et utilisation de celui-ci
KR19990044618A (ko) * 1995-09-13 1999-06-25 다케다 야쿠힌 고교 가부시키가이샤 면역억제제
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992367A (en) * 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOTECHNIQUES, novembre/décembre 1983, pages 198-203; G. SOFER et al.: "Designing an optimal chromatographic purification scheme for proteins" *
J. EXP. MED., vol. 159, janvier 1984, pages 126-136, The Rockefeller University Press; Z. LIAO et al.: "Identification of a specific interleukin 1 inhibitor in the urine of febrile patients" *
J. OF. CLIN. INVEST., vol. 78, octobre 1986, pages 1120-1124, The American Society for Clinical Investigation, Inc.; J.-F. BALAVOINE et al.: "Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s)" *
PROC. NATL. ACAD. SCI. USA, vol. 83, décembre 1986, pages 9119-9123; K.M. BROWN et al.: "Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of interleukin 1" *
THE JOURNAL OF IMMUNOLOGY, vol. 134, no. 6, juin 1985, pages 3868-3875, The American Association of Immunologists; W.P. AREND et al.: "Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor" *
THE JOURNAL OF IMMUNOLOGY, vol. 137, no. 7, 1 octobre 1986, pages 2245-2251, The American Association of Immunologists, US; A. KEMP et al.: "Inhibition of interleukin 1 activity by a factor in submandibular glands of rats" *
THE JOURNAL OF IMMUNOLOGY, vol. 138, no. 5, 1 mars 1987, pages 1457-1463, The American Association of Immunologists, US; T. SCHWARZ et al.: "UV-irradiated epidermal cells produce a specific inhibitor of interleukin 1 activity" *
THE JOURNAL OF THE IMMUNOLOGY, vol. 136, no. 10, 5 mai 1986, pages 3686-3692, The American Association of Immunologists, US; K. TIKU et al.: "Normal human neutrophils are a source of a specific interleukin 1 inhibitor" *

Also Published As

Publication number Publication date
ES2017274A6 (es) 1991-01-16
HK1007748A1 (en) 1999-04-23
FR2621821A1 (fr) 1989-04-21
DK175837B1 (da) 2005-03-21
ES2015348A6 (es) 1990-08-16
EP0341273B1 (fr) 1997-01-08
GB8912533D0 (en) 1989-08-02
GB2220662A (en) 1990-01-17
AU633471B2 (en) 1993-02-04
SE8901342L (sv) 1989-04-13
EP0341273A1 (fr) 1989-11-15
NZ225940A (en) 1992-06-25
DE3855747D1 (de) 1997-02-20
WO1989001946A1 (fr) 1989-03-09
KR0138919B1 (ko) 1998-04-30
EP0341273A4 (en) 1990-09-19
IT1226855B (it) 1991-02-19
KR890701629A (ko) 1989-12-21
ES2017275A6 (es) 1991-01-16
AU2427288A (en) 1989-03-31
JP3217752B2 (ja) 2001-10-15
NL8820676A (nl) 1989-07-03
ATE147408T1 (de) 1997-01-15
DK203189D0 (da) 1989-04-26
JP3014099B2 (ja) 2000-02-28
IL87543A0 (en) 1989-01-31
IT8821743A0 (it) 1988-08-25
JPH10327862A (ja) 1998-12-15
DE3855747T2 (de) 1997-06-12
CA1341026C (fr) 2000-06-13
SE8901342D0 (sv) 1989-04-13
JPH02500643A (ja) 1990-03-08
DK203189A (da) 1989-04-26
ZA886251B (en) 1990-04-25
KR0138654B1 (ko) 1998-04-30

Similar Documents

Publication Publication Date Title
Laurenzi et al. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide
BE1002375A3 (fr) Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.
ATE342964T1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
HUT76875A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
ATE172963T1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
MX9606546A (es) Compuestos inhibidores de la enzima conversiva de interleukina-1 beta.
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
MA29836B1 (fr) Proteines de fusion avec l'albumine
HUP9901874A2 (hu) Humán TNFalfa-t kötő antitestek
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
GB9323165D0 (en) Compounds
AU6150298A (en) No-modified hemoglobins and uses therefor
ATE464378T1 (de) Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung
Wakabayashi et al. Reversible change in physical state of troponin induced by calcium ion
FR2672895B1 (fr) Procede de purification d'une proteine fortement glycosylee.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
AR022836A1 (es) Polipeptido con la actividad biologica de la histidina fosfatasa, el adn que codifica para este polipeptido, un anticuerpo dirigido contra este polipeptidoy una preparacion farmaceutica que contiene este polipeptido
Rey et al. The role of interleukin-2 in T colony formation by human pre-T cells (pTCFC).
Szyfter et al. Inhibitions of DNA sythesis in human lymphocytes proliferation in vitro induced by added DNases
GEP20022764B (en) HIV Protease Inhibitors, Pharmaceutical Compositions and Methods for Inhibiting HIV Protease

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: BIOGEN INC.

Effective date: 19900831